Analysis
Tandem Health, a Stockholm-based clinical AI startup, raised €86.5 million (about $100 million) in a Series B led by EQT's Scaleup Europe Fund, with Kinnevik, Northzone, Amino Collective and Visionaries also participating, Tech Startups reported. The round is the Scaleup Europe Fund's first healthcare investment since it backed Mistral AI and satellite startup Iceye, per EU-Startups.
Tandem builds an AI co-pilot that generates clinical notes during patient consultations in real time, aiming to be what the company calls an AI-native operating system for European healthcare rather than a single-purpose scribe tool. It says it is used by roughly 10,000 care organizations across 14 European markets. The Series B follows a $50 million Series A in 2025, bringing disclosed total funding to roughly €138 million ($160 million).
“It says it is used by roughly 10,000 care organizations across 14 European markets.”
The category Tandem competes in -- ambient clinical documentation -- has a well-funded US leader in Abridge, which has raised at multibillion-dollar valuations backed by a similar thesis: doctors spend hours per day on notes instead of patients, and an AI listener that drafts the chart in real time gives that time back. Nuance's DAX product, now owned by Microsoft, is the incumbent enterprise option inside large US health systems. Tandem's bet is that European healthcare -- fragmented across national systems, languages and reimbursement models in a way the US market is not -- rewards a European-native builder over a US company retrofitting for GDPR and local-language support.
That fragmentation cuts both ways. It is a genuine moat against a single pan-European rollout by a better-funded US competitor, and it is also why no European ambient-documentation company has reached Abridge's scale: winning France does not automatically win Germany, and each national health system negotiates procurement and data-residency requirements separately. Ten thousand care organizations across 14 markets is real distribution, but average revenue per organization -- not logo count -- is the number that determines whether this round's implied valuation holds up at the next raise.
